WO2018150168A1 - Analyte-monitoring device - Google Patents

Analyte-monitoring device Download PDF

Info

Publication number
WO2018150168A1
WO2018150168A1 PCT/GB2018/050384 GB2018050384W WO2018150168A1 WO 2018150168 A1 WO2018150168 A1 WO 2018150168A1 GB 2018050384 W GB2018050384 W GB 2018050384W WO 2018150168 A1 WO2018150168 A1 WO 2018150168A1
Authority
WO
WIPO (PCT)
Prior art keywords
analyte
porous membrane
membrane layer
skin
μηι
Prior art date
Application number
PCT/GB2018/050384
Other languages
French (fr)
Inventor
Dewan Fazlul Hoque Chowdhury
Kartheka Bojan
Sameer AL-KHAWAJA
Vallabh KSHIRSAGAR
Original Assignee
Ndm Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ndm Technologies Limited filed Critical Ndm Technologies Limited
Publication of WO2018150168A1 publication Critical patent/WO2018150168A1/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54373Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • G01N33/5438Electrodes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/002Electrode membranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/14517Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for sweat
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/002Electrode membranes
    • C12Q1/003Functionalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/001Enzyme electrodes
    • C12Q1/005Enzyme electrodes involving specific analytes or enzymes
    • C12Q1/006Enzyme electrodes involving specific analytes or enzymes for glucose
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose

Definitions

  • the present invention relates to a device, and in particular to a device for monitoring an analyte.
  • Such prior art devices can have disadvantages, such as being inaccurate, or insensitive to changes in concentration of an analyte due to poor sensitivity, poor specificity, or limits of detection that are not low enough to detect the low levels of analyte that is extracted. Furthermore, noise generated by inherent features of the devices can also mask the signal generated by the analyte being measured.
  • a further limitation that has been observed is drift in the signal caused by a number of factors, often related to the inherent material properties, for example the drying out of a hydrogel that may be in contact with the skin acting as a diffusion pathway and conducting layer between the skin and the device that measures the analyte signal, such as an electrode measuring the current generated by hydrogen peroxide which in turn is a by-product of the reaction between an analyte and an enzyme present in the system, such as lactase dehydrogenase used to measure lactic acid levels, and glucose oxidase used to measure glucose levels.
  • the present invention seeks to provide a device and method for monitoring an analyte.
  • Figure 1 is an illustration of a device of the invention.
  • Figure 2 shows the results of a monitoring device of the invention.
  • Figure 3 shows the results of a monitoring device of the invention.
  • Figure 4 shows the results of a monitoring device of the invention.
  • Figure 5 shows the results of a monitoring device of the invention.
  • Figure 6 shows the results of a monitoring device of the invention.
  • Figure 7 shows the results of a monitoring device of the invention.
  • Figure 8 shows the results of a monitoring device of the invention.
  • Figure 9 shows the results of a monitoring device of the invention.
  • Figure 10 shows the resu ts of a monitoring device of the invention
  • Figure 1 1 shows the resu ts of a monitoring device of the invention
  • Figure 12 shows the resu ts of a prior art monitoring device.
  • Figure 13 shows the resu ts of a monitoring device of the invention
  • Figure 14 shows the resu ts of a monitoring device of the invention
  • Figure 15 shows the resu ts of a monitoring device of the invention
  • Figure 16 shows the resu ts of a monitoring device of the invention
  • Figure 17 shows the resu ts of a monitoring device of the invention
  • Figure 18 shows the resu ts of a monitoring device of the invention
  • Figure 19 shows the resu ts of a monitoring device of the invention
  • Figure 20 shows the resu ts of a monitoring device of the invention
  • Figure 21 shows the resu ts of a monitoring device of the invention
  • Figure 22 shows the resu ts of a monitoring device of the invention
  • Figure 23 shows the resu ts of a monitoring device of the invention
  • Figure 24 shows the resu ts of a monitoring device of the invention
  • the membrane layer when placed on the skin of a patient the membrane layer is an interface between the skin of the patient and the analyte monitoring means.
  • the analyte monitoring means and the porous membrane layer are preferably separate components.
  • the porous membrane layer comprises nylon. More preferably, the porous membrane layer consists of nylon.
  • the analyte is glucose or lactate.
  • the device does not comprise a gel, such as Carbopol. More specifically, the device may not comprise a hydrogel.
  • the porous membrane layer may not comprise a gel and/or hydrogel.
  • the device is configured to continuously monitor the concentration of the analyte in a patient.
  • the enzyme is glucose oxidase or lactase dehydrogenase.
  • the enzyme has a concentration in the porous membrane layer of 0.45 to 0.60 mg/cm 2 of membrane surface area for a membrane thickness of 158 to 192 ⁇ thickness, or 0.45 mg to 0.60 mg per 0.158 ⁇ 3 to 0.192 ⁇ 3 of the 3-dimensional porous membrane.
  • the analyte monitoring means includes an electrode, the enzyme being deposited on the electrode.
  • the enzyme is deposited on the porous membrane layer by being either physically adsorbed on the porous membrane layer or chemically bonded to the porous membrane layer.
  • the porous membrane layer is a porous hydrophilic polymer layer, optionally wherein the polymer is nylon, preferably nylon 6,6, and more preferably amphoteric nylon 6,6.
  • the porous membrane layer is a porous hydrophobic, or partially hydrophobic layer, optionally wherein the polymer is chemically or physically treated nylon 6,6, or surface functionalised polyethersulfone.
  • the porous membrane layer is a 3-dimensional matrix, optionally wherein the 3-dimensional matrix is nylon 6,6, or surface functionalised polyethersulfone.
  • the porous membrane layer has a thickness of less than 350 ⁇ , more preferably the membrane has a thickness of less than 250 ⁇ .
  • the pores of the porous membrane layer have an average size of from about 0.1 ⁇ to about 2.0 ⁇ , such as from about 0.2 ⁇ to about 1.0 ⁇ , preferably from about 0.3 ⁇ to about 0.5 ⁇ .
  • the porous membrane layer and analyte monitoring means are contiguous.
  • the porous membrane layer and the surface of the skin are contiguous.
  • the patch comprises means for performing iontophoresis, ultrasound, or micro-poration using microneedles or laser light.
  • the analyte monitoring means comprises a counter electrode and a working electrode, and a reference electrode.
  • a device of the invention for monitoring the concentration of an analyte in a patient.
  • a method of monitoring the concentration of an analyte in a patient comprising the steps of:
  • the method involves the step of providing a porous membrane layer that comprises nylon.
  • the method involves the step of providing a porous membrane layer that consists of nylon.
  • the method involves the step of performing iontophoresis or applying ultrasound to the skin, or poration of the skin by laser light or micro needles, in order to receive analyte.
  • the step of performing iontophoresis or applying ultrasound to the skin, and/or poration of the skin by laser light or micro needles is performed prior to application of the device to the skin.
  • the analyte is glucose or lactate
  • the method comprises the step of oxidising the received glucose or lactate to produce hydrogen peroxide.
  • the method comprises the step of detecting the level of hydrogen peroxide produced by the analyte detection means.
  • the present invention concerns devices and methods relating to monitoring analytes in an animal body, particularly a human body.
  • the analytes are moieties which are useful in monitoring, for example in connection with the health of the subject.
  • analytes whose concentration can change with time.
  • suitable analytes include glucose, lactate, phenylephrine, drugs/medicines, and ions in the plasma.
  • Preferred analytes include glucose and lactate resulting from lactic acid build up in muscles.
  • the level of glucose in a subject varies with time, and it is useful to monitor the level in the prevention and treatment of certain diseases and conditions, such as diabetes and hyperglycemia.
  • Some prior art monitoring systems aimed at monitoring the level of analytes such as glucose suffer from disadvantages, including lack of sensitivity, high noise levels and an inability to monitor changes in concentration in a real-time or near-real time manner.
  • the present invention provided a device and method to monitor the level of an analyte.
  • a device 2 according to the invention is shown.
  • the device 2 is in the form of a patch placed on the skin 4 of a subject.
  • the dermal patch device 2 comprises a porous membrane 6 placed onto the skin 4 of the subject.
  • the membrane 6 is positioned such that it interfaces with the face of an electrode 8.
  • an analyte present in the subject leaves the skin 4 and enters the membrane 6.
  • the porous membrane 6 comprises an enzyme which acts upon the analyte.
  • the enzyme is bound in some way to the membrane 6 as will be discussed in more detail below.
  • the porous membrane is maintained on the skin by the use of a peripheral adhesive such as silicone adhesive or acryclic adhesive, or by forming a vacuum seal around the device, without the use of adhesive.
  • the device of the present invention is preferably in the form of a patch, more preferably a dermal patch.
  • the enzyme acts on the analyte to facilitate a chemical reaction.
  • the reaction produces a moiety which is detected by the electrode 8.
  • the enzyme glucose oxidase (GOx) can be used in the device of the present invention to monitor glucose in a subject.
  • the glucose oxidase enzyme (GOx) also known as notatin is an oxido-reductase that catalyses the oxidation of glucose to hydrogen peroxide and D-glucono-5-lactone.
  • the resultant hydrogen peroxide is electrochemically detected by the electrode 8, which is connected to suitable electronic circuitry and power supply to enable the amperometric detection of the signal generated by the reaction of the analyte with the enzyme.
  • the electrical signal is related to the amount of hydrogen peroxide, which itself is related to the amount of glucose.
  • the enzyme is deposited on the electrode 8, rather than in the membrane 6.
  • the membrane 6 facilitates diffusion of the analyte from the skin 4 towards the electrode 8.
  • the enzyme then acts on the analyte to cause and chemical reaction which is detected by the electrode 8 in the same manner as described above.
  • the membrane 6 is a nylon membrane.
  • Nylon is a generic designation for a family of synthetic polymers, based on aliphatic or semi-aromatic poiyamides. Commercially, nylon polymer is made by reacting monomers which are either lactams, acid/amines or stoichiometric mixtures of diamines (-NH2) and diacids (-COOH). Mixtures of these can be polymerized together to make copolymers and it will be appreciated that Nylon polymers can be mixed with a wide variety of additives to achieve many different property variations, yet described broadly as Nylon.
  • Nylon A key property of the chemical structure of Nylon is repeating monomers in a linear chain, in contrast to cellulose, polyester and other porous polymer substrates that predominantly include cyclic structures or benzene rings, it is thought the linear nature of the monomeric chains that build up the polymer help support better diffusion due to the absence of interfering charges from cyclic structures and benzene rings' electron orbitais.
  • Two fundamental properties of Nylon that prevail over other types of polymer substrates for this application have been determined as firstly their moisture retention affinity, which helps to avoid signal drift (which would otherwise occur where the affinity to retain moisture is poor), and secondly the absence of residues that can lead to noise and erroneous signals that often cannot be eliminated/depleted.
  • Nylon provides a fixed rigid volume of moisture
  • porous nylon provides a large surface area for diffusion through unimpeded liquid moisture as opposed to a polymer network of a semi solid hydroge!, and the surface area further provides a large area for anchoring enzymes whilst providing unobstructed conduits for the diffusion of the byproduct of the reaction between an analyte such as lactate or glucose and an enzyme.
  • an analyte such as lactate or glucose and an enzyme.
  • lactase dehydrogenase may be used to measure lactate levels extracted from the skin resulting from the build-up of lactic acid in muscle tissue.
  • Various methods could be used to help the analyte to pass through the skin and into the membrane. These methods include iontophoresis, ultrasound and skin poration using physical ablation with pulsed concentrated laser beams, or microneedles. General skin abrasion has also been used to enhance the permeation and/or diffusion of analytes out of the body through the skin. These steps can be alone or in combination, and can be performed before the device is applied to the subject, and/or after the device has been applied to the subject.
  • the membrane does not contain a gel, and more specifically does not contain a hydrogel.
  • a gel or hydrogel can reduce analyte sensitivity and adversely affect the signal to noise ratio of the signal. This may be caused by the presence of components in the gel or hydrogel such as buffers and surfactants and the gel-forming material itself, all of which have been noted to contribute to the noise levels to varying degrees.
  • the present invention contemplates using a porous membrane, such as a nylon mesh, or a 3D matrix that is a 'solid' system.
  • a porous membrane such as a nylon mesh, or a 3D matrix that is a 'solid' system.
  • dehydration is very low compared to gels.
  • the membrane used in the invention is a porous membrane.
  • the membranes are preferably hydrophobic, or partially hydrophobic.
  • the membranes are preferably hydrophilic, or partially hydrophilic.
  • the membrane is amphoteric, either on the surface alone or on the surface and throughout the matrix, or within the 3-dimensional matrix alone. Amphoteric membranes have been found to provide a higher level of consistency in absorption and adsorption of the enzyme solution, and have also shown remarkably strong precision in human studies, whereby precision is measured by applying two devices to a single patient, for example one on each arm, and measuring the closeness of the signals obtained by each device.
  • the devices of the invention comprise a membrane that comprises an enzyme.
  • the enzyme may be bound to the membrane by physical adsorption, entrapment (for example within a bead), covalent bonding or electrostatic bonding, and so on.
  • a preferred method of binding the enzyme to the porous membrane is with the use of metal nanoparticles or the use of a cross-linking agent such as glutaraldehyde.
  • a cross-linking agent such as glutaraldehyde.
  • the enzyme may be associated with the nanoparticles in a number of ways, such as covalent bonds and electrostatic interactions. Gold nanoparticles are used in a preferred embodiment of the invention.
  • the enzyme has a concentration in the porous membrane layer of 0.45 to 0.60 mg/cm 2 of membrane surface area for a membrane thickness of 158 to 192 ⁇ thickness, or 0.45 mg to 0.60 mg per 0.158 ⁇ 3 to 0.192 ⁇ 3 of the 3-dimensional porous membrane.
  • the enzyme is present in the membrane in an amount of less than 0.8 mg/cm 2 .
  • the concentration is within the range 0.35 to 0.70 mg/cm 2 .
  • the concentration is within the range 0.45 to 0.60 mg/cm 2 , or this may be expressed as amount of glucose oxidase, dissolved in a suitable aqueous system such as water or buffer, per 0.158 ⁇ 3 to 0.192 ⁇ 3 of the 3-dimensional porous membrane, for membrane thicknesses of 145 to 170 ⁇ .
  • Glucose Oxidase (GOx) was prepared as a dispersion surrounded by Gold nanoparticles according to methods available in the published literature. 5nm and 10nm gold nanoparticles were studied. It was found that membranes coated with gold nanoparticles where the gold particle size was 10nm provided superior results to 5nm gold particles, whereby 0.27mg Glucose Oxidase was mixed with 3ml of a nano-gold suspension (containing 5.70 x 10 12 gold particles per millilitre). Additionally, the results shown in Figure 2 indicates the following findings: 1. There is a linear increase in the glucose concentration when glucose solution is added incrementally (glucose solution addition commencement is indicated by the line between about 35 and 90 minutes). The linearity shows a significantly higher gradient (therefore sensor sensitivity level) as compared with the use of hydrogels.
  • the depletion of the signal started immediately after the last glucose dispense with a rapidly decreasing slope indicating a rapid depletion rate, as compared with hydrogels which has shown longer depletion rates.
  • a rapid depletion rate is very important to maintain a strong dynamic relationship between rise and falls in blood glucose levels for example, and the ability of the sensor to detect it without significant time lags.
  • the results shown in Figures 7 and 8 depict the effect of concentration of Glucose Oxidase and ratio of glucose oxidase to Glutaraldehyde, with respect to the response signal obtained from glucose dispensed on a membrane-based medium.
  • glucose oxidase:glutaraldehyde ratio is 0.4 (first graph) the results are inconclusive without any trend observed.
  • the ratio is 0.8 (second graph)
  • the ratio of glucose oxidase to glutaraldehyde is preferably greater than 0.5 (2 to 1 glucose oxidase to glutaraldehyde).
  • the solid mesh structure of the membrane allows liquid to be held within it, such as water, buffer or some other non-interfering medium through which diffusion of the relevant analytes or enzyme reaction products can occur, as they make their way to the electrode surface.
  • liquid can be difficult to retain in the membrane for long periods of time, since the liquid is easily drawn in where the membrane is hydrophilic.
  • Using a hydrophobic, or partially hydrophobic membrane, or a membrane that has reduced hydrophilicity will require additional energy input to drive the diffusion medium/liquid through it. This energy may be heat, sonication, agitation etc., or a combination of these.
  • Hydrogel/PBS A problem faced with the use of Hydrogel/PBS systems is a current signal well before the analyte reaction that is to be measured.
  • the signal obtained only with Hydrogel/PBS is the artefact/noise for the biosensor system.
  • the current signal obtained from the hydrogel/PBS system is due the dissociation of molecules into ions (Hydrogel) and free flow of ions (PBS) influenced by the current applied on the working electrode of the sensor where Hydrogel/PBS is utilised.
  • the ions from the interface medium contribute to the current and result in an unwanted signal.
  • the prior art interface between the skin surface and the sensor is replaced by a porous membrane which comprises an enzyme.
  • the porous membrane acts as a medium for the analytes from the skin to the sensor's working electrode. This eliminates the unwanted current signal by the ions present in the prior art systems due to the elimination of such extraneous ions and materials through interaction with the membranes 3-dimensional surface area.
  • Figure 14 shows the results from a prior art device
  • Figure 15 shows the results from a device according to the invention.
  • a Membrane as used in the present invention are advantageous as compared to a prior art Hydrogel/Buffer Solution: 1. Porous to allow the analyte to pass through, preferably with a porosity of less than 2 ⁇ pore diameter - more preferably less than 1 ⁇ pore diameter, and even more preferably 0.45 ⁇ pore diameter - becoming a selective membrane and thus keeping other components away from the sensor working electrode.
  • the devices of the present invention have a sensor design approach which is to provide a substrate for the chemistry and the amperometric detection in a way that provides high signal to noise ratio, and rapid signal response and depletion, as follows:
  • porous substrate comprising the enzyme of the specific analyte being measured using an immobilisation technique, which may be ionic, covalent, hydrogen or electrostatic bonding.
  • the working electrode of the sensor has a voltage applied to it providing an electric field around the surface of the membrane, activating the reaction product, such as H2O2 from the membrane to reach the working electrode due to electro-diffusion.
  • This scenario takes place, since moieties like H2O2 are electro-active compounds due to its dipole moment binding (molecular structural property).
  • a reaction product reaches the working electrode resulting in the current signal equivalent to the concentration of the reaction product which is directly proportional to the specific analyte measured.
  • the membrane A performs better since its net charge can be controlled by the pH activity of the chemical reaction.
  • the change in net charge is adaptable in Membrane A which helps in the signal strength as the current flow can be high, as most of the time membrane A remains neutral whereas Membrane C has a negative charge with it that inhibits the current, which is also observed in the experimental results.
  • Membrane A Sensitivity and lower concentration detection is possible in Membrane A. This is because Membrane A is a nylon based filter and does not contain any functional groups or charges, making the membrane A non-functionalised, providing a great response to analyte monitoring. While Membrane C also contains nylon material, it has charges and functional groups for derivatization.
  • the device was used with membranes A and C in a human study in an insulin-dependent diabetic subject.
  • the glucose measurements were taken once every 5 minutes over a period of up to 10 hours, during continuous device application to the arm of the patient.
  • Finger prick glucose measurements were also taken at pre-defined time intervals of up to hourly frequency.
  • Two devices were worn simultaneously, one on each arm to measure precision as well as accuracy. The results are summarised in the table below, and also shown in figures 21 to 24.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

An analyte-monitoring device comprising: a porous membrane layer; an analyte monitoring means and an enzyme; wherein, when placed on the skin of a patient the membrane layer is an interface between the skin of the patient and the analyte monitoring means. The use of a device for monitoring the concentration of an analyte in a patient, and a method of monitoring the concentration of an analyte in a patient are disclosed.

Description

ANALYTE-MONITORING DEVICE
The present invention relates to a device, and in particular to a device for monitoring an analyte.
There have been many attempts to monitor the level of an analyte within the body of an animal. Some of these attempts have been quite intrusive, involving taking a sample of tissue or blood or the insertion of a sensor inside the skin of a human or animal subject. Other attempts have tried to assess the level of a particular substance in a less intrusive manner. One type of attempt has been to utilise a device placed in contact with an animal's body, such as in contact with the skin to measure an analyte that is either passively or actively extracted via pores in the skin.
Such prior art devices can have disadvantages, such as being inaccurate, or insensitive to changes in concentration of an analyte due to poor sensitivity, poor specificity, or limits of detection that are not low enough to detect the low levels of analyte that is extracted. Furthermore, noise generated by inherent features of the devices can also mask the signal generated by the analyte being measured. A further limitation that has been observed is drift in the signal caused by a number of factors, often related to the inherent material properties, for example the drying out of a hydrogel that may be in contact with the skin acting as a diffusion pathway and conducting layer between the skin and the device that measures the analyte signal, such as an electrode measuring the current generated by hydrogen peroxide which in turn is a by-product of the reaction between an analyte and an enzyme present in the system, such as lactase dehydrogenase used to measure lactic acid levels, and glucose oxidase used to measure glucose levels.
The present invention seeks to provide a device and method for monitoring an analyte.
The present invention will now be described, by way of example, with reference to the following figures, in which:
Figure 1 is an illustration of a device of the invention.
Figure 2 shows the results of a monitoring device of the invention.
Figure 3 shows the results of a monitoring device of the invention.
Figure 4 shows the results of a monitoring device of the invention.
Figure 5 shows the results of a monitoring device of the invention.
Figure 6 shows the results of a monitoring device of the invention. Figure 7 shows the results of a monitoring device of the invention.
Figure 8 shows the results of a monitoring device of the invention.
Figure 9 shows the results of a monitoring device of the invention.
Figure 10 shows the resu ts of a monitoring device of the invention
Figure 1 1 shows the resu ts of a monitoring device of the invention
Figure 12 shows the resu ts of a prior art monitoring device.
Figure 13 shows the resu ts of a monitoring device of the invention
Figure 14 shows the resu ts of a monitoring device of the invention
Figure 15 shows the resu ts of a monitoring device of the invention
Figure 16 shows the resu ts of a monitoring device of the invention
Figure 17 shows the resu ts of a monitoring device of the invention
Figure 18 shows the resu ts of a monitoring device of the invention
Figure 19 shows the resu ts of a monitoring device of the invention
Figure 20 shows the resu ts of a monitoring device of the invention
Figure 21 shows the resu ts of a monitoring device of the invention
Figure 22 shows the resu ts of a monitoring device of the invention
Figure 23 shows the resu ts of a monitoring device of the invention
Figure 24 shows the resu ts of a monitoring device of the invention According to the present invention, there is provided an analyte-monitoring device comprising:
a porous membrane layer;
an analyte monitoring means; and
an enzyme deposited on the porous membrane layer and/or the analyte monitoring means;
wherein, when placed on the skin of a patient the membrane layer is an interface between the skin of the patient and the analyte monitoring means.
The analyte monitoring means and the porous membrane layer are preferably separate components.
Preferably, the porous membrane layer comprises nylon. More preferably, the porous membrane layer consists of nylon.
Preferably, the analyte is glucose or lactate. Conveniently, the device does not comprise a gel, such as Carbopol. More specifically, the device may not comprise a hydrogel. In particular, the porous membrane layer may not comprise a gel and/or hydrogel. Advantageously, the device is configured to continuously monitor the concentration of the analyte in a patient.
Preferably, the enzyme is glucose oxidase or lactase dehydrogenase. Conveniently, the enzyme has a concentration in the porous membrane layer of 0.45 to 0.60 mg/cm2 of membrane surface area for a membrane thickness of 158 to 192 μηι thickness, or 0.45 mg to 0.60 mg per 0.158 μηι3 to 0.192μηι3 of the 3-dimensional porous membrane. Optionally, the analyte monitoring means includes an electrode, the enzyme being deposited on the electrode.
Alternatively, the enzyme is deposited on the porous membrane layer by being either physically adsorbed on the porous membrane layer or chemically bonded to the porous membrane layer.
Preferably, the porous membrane layer is a porous hydrophilic polymer layer, optionally wherein the polymer is nylon, preferably nylon 6,6, and more preferably amphoteric nylon 6,6.
Conveniently, the porous membrane layer is a porous hydrophobic, or partially hydrophobic layer, optionally wherein the polymer is chemically or physically treated nylon 6,6, or surface functionalised polyethersulfone. Advantageously, the porous membrane layer is a 3-dimensional matrix, optionally wherein the 3-dimensional matrix is nylon 6,6, or surface functionalised polyethersulfone.
Preferably, the porous membrane layer has a thickness of less than 350 μηι, more preferably the membrane has a thickness of less than 250 μηι. Conveniently, the pores of the porous membrane layer have an average size of from about 0.1 μηι to about 2.0 μηι, such as from about 0.2 μηι to about 1.0 μηι, preferably from about 0.3 μηι to about 0.5 μηι. Advantageously, the porous membrane layer and analyte monitoring means are contiguous.
Preferably, when placed on the surface of the skin of the skin of a patient, the porous membrane layer and the surface of the skin are contiguous.
Conveniently, the patch comprises means for performing iontophoresis, ultrasound, or micro-poration using microneedles or laser light.
Advantageously, the analyte monitoring means comprises a counter electrode and a working electrode, and a reference electrode.
According to another aspect of the invention there is provided the use of a device of the invention for monitoring the concentration of an analyte in a patient. According to another aspect of the invention, there is provided a method of monitoring the concentration of an analyte in a patient comprising the steps of:
a) applying a device of the invention to the skin of the patient such that the porous membrane layer of the device is hydrated and in contact with the skin;
b) receiving analyte from the skin into the porous membrane layer;
c) converting the received analyte via the enzyme deposited in the porous membrane layer and/or on the analyte monitoring means; and
d) generating a signal representative of the level of received analyte via the analyte monitoring means. Optionally, the method involves the step of providing a porous membrane layer that comprises nylon. Preferably, the method involves the step of providing a porous membrane layer that consists of nylon.
Preferably, the method involves the step of performing iontophoresis or applying ultrasound to the skin, or poration of the skin by laser light or micro needles, in order to receive analyte. Conveniently, the step of performing iontophoresis or applying ultrasound to the skin, and/or poration of the skin by laser light or micro needles is performed prior to application of the device to the skin.
Advantageously, the analyte is glucose or lactate, and the method comprises the step of oxidising the received glucose or lactate to produce hydrogen peroxide.
Preferably, the method comprises the step of detecting the level of hydrogen peroxide produced by the analyte detection means.
The present invention concerns devices and methods relating to monitoring analytes in an animal body, particularly a human body. The analytes are moieties which are useful in monitoring, for example in connection with the health of the subject. Of particular interest are analytes whose concentration can change with time. Example of suitable analytes include glucose, lactate, phenylephrine, drugs/medicines, and ions in the plasma. Preferred analytes include glucose and lactate resulting from lactic acid build up in muscles. The level of glucose in a subject varies with time, and it is useful to monitor the level in the prevention and treatment of certain diseases and conditions, such as diabetes and hyperglycemia.
Some prior art monitoring systems aimed at monitoring the level of analytes such as glucose suffer from disadvantages, including lack of sensitivity, high noise levels and an inability to monitor changes in concentration in a real-time or near-real time manner.
The present invention provided a device and method to monitor the level of an analyte. Turning to Figure 1 , a device 2 according to the invention is shown. The device 2 is in the form of a patch placed on the skin 4 of a subject. The dermal patch device 2 comprises a porous membrane 6 placed onto the skin 4 of the subject. The membrane 6 is positioned such that it interfaces with the face of an electrode 8. In use, an analyte present in the subject leaves the skin 4 and enters the membrane 6. In one embodiment, the porous membrane 6 comprises an enzyme which acts upon the analyte. The enzyme is bound in some way to the membrane 6 as will be discussed in more detail below. In some embodiments, the porous membrane is maintained on the skin by the use of a peripheral adhesive such as silicone adhesive or acryclic adhesive, or by forming a vacuum seal around the device, without the use of adhesive.
The device of the present invention is preferably in the form of a patch, more preferably a dermal patch.
The enzyme acts on the analyte to facilitate a chemical reaction. The reaction produces a moiety which is detected by the electrode 8. For example, the enzyme glucose oxidase (GOx) can be used in the device of the present invention to monitor glucose in a subject. The glucose oxidase enzyme (GOx) also known as notatin is an oxido-reductase that catalyses the oxidation of glucose to hydrogen peroxide and D-glucono-5-lactone. The resultant hydrogen peroxide is electrochemically detected by the electrode 8, which is connected to suitable electronic circuitry and power supply to enable the amperometric detection of the signal generated by the reaction of the analyte with the enzyme. The electrical signal is related to the amount of hydrogen peroxide, which itself is related to the amount of glucose.
In another embodiment, the enzyme is deposited on the electrode 8, rather than in the membrane 6. The membrane 6 facilitates diffusion of the analyte from the skin 4 towards the electrode 8. The enzyme then acts on the analyte to cause and chemical reaction which is detected by the electrode 8 in the same manner as described above.
In a preferred embodiment, the membrane 6 is a nylon membrane. Nylon is a generic designation for a family of synthetic polymers, based on aliphatic or semi-aromatic poiyamides. Commercially, nylon polymer is made by reacting monomers which are either lactams, acid/amines or stoichiometric mixtures of diamines (-NH2) and diacids (-COOH). Mixtures of these can be polymerized together to make copolymers and it will be appreciated that Nylon polymers can be mixed with a wide variety of additives to achieve many different property variations, yet described broadly as Nylon. A key property of the chemical structure of Nylon is repeating monomers in a linear chain, in contrast to cellulose, polyester and other porous polymer substrates that predominantly include cyclic structures or benzene rings, it is thought the linear nature of the monomeric chains that build up the polymer help support better diffusion due to the absence of interfering charges from cyclic structures and benzene rings' electron orbitais. Two fundamental properties of Nylon that prevail over other types of polymer substrates for this application have been determined as firstly their moisture retention affinity, which helps to avoid signal drift (which would otherwise occur where the affinity to retain moisture is poor), and secondly the absence of residues that can lead to noise and erroneous signals that often cannot be eliminated/depleted. This has been generally overlooked in the past as sensors applied to the body have generally involved the use of hydrogels into which enzymes and mediators have been embedded, as exemplified by patents filed by Cygnus Inc. In this invention we have demonstrated that the use of hydrogels is detrimental unless complex hydrogels manufactured using elaborate and expensive processes are applied, rendering the final product commercially uneconomical; and despite this hydrogels suffer from the absorption of moisture from the skin that increases its mass causing signal drift. The use of Nylon on the other hand provides a fixed rigid volume of moisture, and porous nylon provides a large surface area for diffusion through unimpeded liquid moisture as opposed to a polymer network of a semi solid hydroge!, and the surface area further provides a large area for anchoring enzymes whilst providing unobstructed conduits for the diffusion of the byproduct of the reaction between an analyte such as lactate or glucose and an enzyme. The uniqueness of the positive attributes determined for Nylon and the ability to use it in the present invention allow for the monitoring of analytes that are orders of magnitude lower in concentration, as low as pico gram quantities.
Other enzymes can be used in a similar way to monitor the levels of other analytes. For example, lactase dehydrogenase may be used to measure lactate levels extracted from the skin resulting from the build-up of lactic acid in muscle tissue.
Various methods could be used to help the analyte to pass through the skin and into the membrane. These methods include iontophoresis, ultrasound and skin poration using physical ablation with pulsed concentrated laser beams, or microneedles. General skin abrasion has also been used to enhance the permeation and/or diffusion of analytes out of the body through the skin. These steps can be alone or in combination, and can be performed before the device is applied to the subject, and/or after the device has been applied to the subject.
Preferably, the membrane does not contain a gel, and more specifically does not contain a hydrogel. The applicant has found that the presence of a gel or hydrogel can reduce analyte sensitivity and adversely affect the signal to noise ratio of the signal. This may be caused by the presence of components in the gel or hydrogel such as buffers and surfactants and the gel-forming material itself, all of which have been noted to contribute to the noise levels to varying degrees.
Also, in a polymer membrane such as Nafion is added then an issue is that diffusion is restricted leading to poor signal. Also, gels have been found to dehydrate over time leading to signal drift over time which must be corrected by multiple calibrations which is not ideal from a patient perspective.
The present invention contemplates using a porous membrane, such as a nylon mesh, or a 3D matrix that is a 'solid' system. This leads to several advantages, including a reduction in background noise and very good diffusion. Also, interfering species can be trapped in the matrix and therefore prevented from reaching the electrode thus giving clean low noise signals. In addition, given the solid nature of the membrane substrate, dehydration is very low compared to gels.
The membrane used in the invention is a porous membrane. In some applications, the membranes are preferably hydrophobic, or partially hydrophobic. In some applications, the membranes are preferably hydrophilic, or partially hydrophilic. Furthermore, in some applications the membrane is amphoteric, either on the surface alone or on the surface and throughout the matrix, or within the 3-dimensional matrix alone. Amphoteric membranes have been found to provide a higher level of consistency in absorption and adsorption of the enzyme solution, and have also shown remarkably strong precision in human studies, whereby precision is measured by applying two devices to a single patient, for example one on each arm, and measuring the closeness of the signals obtained by each device. These amphoteric properties have also yielded significantly higher accuracy of analyte levels measured using the device, for example glucose measurements, when compared with finger prick glucose measurements. Such levels of accuracy, specificity and elimination of noise and signal drift using this type of membrane has not previously been reported in literature and provides a significant advance on the current state of the art, with tangible benefits to end users of this type of system for continuous monitoring. These membranes whilst mentioned in passing in numerous patents and some published literature, for this type of monitoring, have not been investigated in any detail according to the literature, and have been widely used in laboratory settings for conducting laboratory based tests, or used in instrumentation that is designed for separation and measurement of analytes. The devices of the invention comprise a membrane that comprises an enzyme. It has been found by the applicant that good results are achieved when the enzyme is bound in some way to the membrane. The enzyme may be bound to the membrane by physical adsorption, entrapment (for example within a bead), covalent bonding or electrostatic bonding, and so on.
A preferred method of binding the enzyme to the porous membrane is with the use of metal nanoparticles or the use of a cross-linking agent such as glutaraldehyde. Where gold nanoparticles are used the enzyme may be associated with the nanoparticles in a number of ways, such as covalent bonds and electrostatic interactions. Gold nanoparticles are used in a preferred embodiment of the invention.
Conveniently, the enzyme has a concentration in the porous membrane layer of 0.45 to 0.60 mg/cm2 of membrane surface area for a membrane thickness of 158 to 192 μηι thickness, or 0.45 mg to 0.60 mg per 0.158 μηι3 to 0.192μηι3 of the 3-dimensional porous membrane. In general, the enzyme is present in the membrane in an amount of less than 0.8 mg/cm2. Preferably the concentration is within the range 0.35 to 0.70 mg/cm2. More preferably the concentration is within the range 0.45 to 0.60 mg/cm2, or this may be expressed as amount of glucose oxidase, dissolved in a suitable aqueous system such as water or buffer, per 0.158 μηι3 to 0.192μηι3 of the 3-dimensional porous membrane, for membrane thicknesses of 145 to 170 μηι.
Examples
Binding of GOx to Membranes
Glucose Oxidase (GOx) was prepared as a dispersion surrounded by Gold nanoparticles according to methods available in the published literature. 5nm and 10nm gold nanoparticles were studied. It was found that membranes coated with gold nanoparticles where the gold particle size was 10nm provided superior results to 5nm gold particles, whereby 0.27mg Glucose Oxidase was mixed with 3ml of a nano-gold suspension (containing 5.70 x 1012 gold particles per millilitre). Additionally, the results shown in Figure 2 indicates the following findings: 1. There is a linear increase in the glucose concentration when glucose solution is added incrementally (glucose solution addition commencement is indicated by the line between about 35 and 90 minutes). The linearity shows a significantly higher gradient (therefore sensor sensitivity level) as compared with the use of hydrogels.
2. The depletion of the signal started immediately after the last glucose dispense with a rapidly decreasing slope indicating a rapid depletion rate, as compared with hydrogels which has shown longer depletion rates. A rapid depletion rate is very important to maintain a strong dynamic relationship between rise and falls in blood glucose levels for example, and the ability of the sensor to detect it without significant time lags.
3. The noise signal is very low with respect to the lowest glucose concentration signal. GOx only on Membrane
The results obtained for GOx only on a membrane were inconsistent throughout the studies. In most cases, they did not respond to the amount of glucose added, but instead resulted in a depleting signal. The results are shown in Figures 3, 4 and 5. This further supports the contribution of the nano-gold in anchoring the enzyme in an effective manner to allow the extracted analyte, such as glucose to be presented to the enzyme for a consistent and reproducible reaction to occur.
Glutaraldehyde-GOx on Membrane
The results are shown in Figure 6. The ascending portions of the line indicates the incremental addition of glucose solutions. The results indicate:
1. Depletion occurs immediately after glucose addition is stopped.
2. Noise is noticeable at lower glucose concentrations
Concentration of GOx: GLU on Membrane
The results shown in Figures 7 and 8 depict the effect of concentration of Glucose Oxidase and ratio of glucose oxidase to Glutaraldehyde, with respect to the response signal obtained from glucose dispensed on a membrane-based medium. When the glucose oxidase:glutaraldehyde ratio is 0.4 (first graph) the results are inconclusive without any trend observed. When the ratio is 0.8 (second graph), there is a clear linear increase (orange line) observed with addition of glucose, followed by a drop in glucose level when the addition of glucose is stopped indicating immediate depletion of glucose levels. The ratio of glucose oxidase to glutaraldehyde is preferably greater than 0.5 (2 to 1 glucose oxidase to glutaraldehyde).
The solid mesh structure of the membrane allows liquid to be held within it, such as water, buffer or some other non-interfering medium through which diffusion of the relevant analytes or enzyme reaction products can occur, as they make their way to the electrode surface. However, the liquid can be difficult to retain in the membrane for long periods of time, since the liquid is easily drawn in where the membrane is hydrophilic. Using a hydrophobic, or partially hydrophobic membrane, or a membrane that has reduced hydrophilicity will require additional energy input to drive the diffusion medium/liquid through it. This energy may be heat, sonication, agitation etc., or a combination of these. It follows that a similarly high level of energy will be required to remove the liquid from the membrane, i.e., it will have a reduced propensity to exit the membrane in the absence of an energy source, as a result of which the membrane will retain the liquid for far longer periods, leading to more controlled diffusion, and absence of drift caused by a reduction of the liquid content of the membrane/drying out of the membrane over time. This drying out usually occurs even when there is a hermetic seal around the skin, since the skin itself can absorb some of the moisture/liquid.
Background Signal - Use of Hydrogel/PBS Buffer Solution
The use of prior art hydrogel/PBS systems to act as an interface between the skin surface and the working electrode of the sensor has disadvantages. The analytes extracted from the skin through Iontophoresis need to diffuse through the hydrogel system to reach the working electrode for the specific analyte (e.g. glucose) to react with the enzyme coated on the working electrodes of the sensor, for the measurement of the analyte to be measured. A typical response to additions of glucose to a prior art hydrogel device is illustrated in Figures 9 and 10. The concentrations of analyte added and the current signal obtained are aligned in parallel at same time periods
A problem faced with the use of Hydrogel/PBS systems is a current signal well before the analyte reaction that is to be measured. The signal obtained only with Hydrogel/PBS is the artefact/noise for the biosensor system.
The current signal obtained from the hydrogel/PBS system is due the dissociation of molecules into ions (Hydrogel) and free flow of ions (PBS) influenced by the current applied on the working electrode of the sensor where Hydrogel/PBS is utilised. The ions from the interface medium contribute to the current and result in an unwanted signal. The prior art interface between the skin surface and the sensor is replaced by a porous membrane which comprises an enzyme. The porous membrane acts as a medium for the analytes from the skin to the sensor's working electrode. This eliminates the unwanted current signal by the ions present in the prior art systems due to the elimination of such extraneous ions and materials through interaction with the membranes 3-dimensional surface area.
The results obtained from the porous membrane as the interface/medium for the Iontophoresis extraction analyte eliminates the unwanted/background signal produced with either hydrogel or buffer solutions as an interface medium. An example of the response from a device according to the invention is shown in Figure 1 1.
The noise resulting from the prior art Hydrogel/PBS systems on the sensor dominates the actual signal (Analyte measurement) making the SNR very low. (SNR ≡ 2, which is considerably low for the sensor). Experimental results from a prior art hydrogel device are shown in Figure 12.
The noise level in the membrane interface of embodiments of the present invention is below the actual signal of the analyte measured, and the SNR is relatively high when compared to other interfaces mentioned above. (SNR ≡ 1 1 , calculated from the experimental results). Experimental results from a device according to the invention are shown in Figure 13. Sensitivity of the Sensor
The use of the membrane in accordance with the present invention increases the sensitivity of the signal tremendously, as depicted in Figures 14 and 15. Figure 14 shows the results from a prior art device and Figure 15 shows the results from a device according to the invention.
Membranes
The following properties of a Membrane as used in the present invention are advantageous as compared to a prior art Hydrogel/Buffer Solution: 1. Porous to allow the analyte to pass through, preferably with a porosity of less than 2 μηι pore diameter - more preferably less than 1 μηι pore diameter, and even more preferably 0.45 μηι pore diameter - becoming a selective membrane and thus keeping other components away from the sensor working electrode.
2. Intrinsically Hydrophilic membranes entrapping the water and the other components, thus not contacting the working electrode which will result in ion formation and therefore the current, avoiding giving rise to the unwanted signal. 3. Low background Signal - since the membranes used in the invention have low or substantially no free ion, they enhance the chemical reaction without the interference of the background signals mentioned above.
So, the devices of the present invention have a sensor design approach which is to provide a substrate for the chemistry and the amperometric detection in a way that provides high signal to noise ratio, and rapid signal response and depletion, as follows:
1. The membrane section where the chemical reactions take place and/or rapid diffusion of an analyte can occur, whilst filtering out extraneous signal generating matter.
2. The sensing section where amperometric measurements takes place and where the chemical reaction between reactant species can also take place with low signal to noise ratio. This Design approach is taken to provide a real time measurement with a faster accumulation/depletion rate to give more sensitive and more accurate monitoring.
Working Principle of the Designed Bio-sensor 1. Chemical Reaction Field
The porous substrate comprising the enzyme of the specific analyte being measured using an immobilisation technique, which may be ionic, covalent, hydrogen or electrostatic bonding.
Thus, when the specific analyte enters the porous substrate, it reacts with the coated enzyme leading to reaction products. 2. Electric Field
The working electrode of the sensor has a voltage applied to it providing an electric field around the surface of the membrane, activating the reaction product, such as H2O2 from the membrane to reach the working electrode due to electro-diffusion. This scenario takes place, since moieties like H2O2 are electro-active compounds due to its dipole moment binding (molecular structural property). Thus, a reaction product reaches the working electrode resulting in the current signal equivalent to the concentration of the reaction product which is directly proportional to the specific analyte measured.
The above helps with the following scenarios:
1. Low background Signal
2. Signal to noise ratio of the sensor is high
3. Increased Sensitivity of the sensor Study on membranes Bio-dyne A and C
Three continuous cumulative experiments were done both on Bio-dyne Membrane A & C twice, on each membrane.
TriaH Increment Decrease
Trial 2 1 - 34 μΜ Increment only up to Increment only up to
30 μΜ 30 μΜ
Trial 3 4 - 26 μΜ Incremental Incremental
The results are shown in Figures 16 to 18. Observation from Results
Figure imgf000016_0001
Fluctuating Gradient - Decreasing Gradient Mem A has better Increasing in most response relative to points Mem C. Mem A has better sensitivity
Product Bio dyne A Membrane Bio dyne C Membrane
Description Amphoteric Nylon 6,6 Negatively-charged
Nylon 6.6
Works best for: Colony/Plaque Lifts. DNA and RNA Reverse Dot Blots
Also, suited for: Transfers Protein Immobilization.
Gene Probe Assays. DNA Fingerprinting. Affinity Purification. Nucleic Acid Dot/Slot Blots. Replica Plating. ELISAs
ELISAs
Advantages - High sensitivity - Low background - Net - Negative charge over charge can be controlled broad pH range by changing pH - Ability to strip and re- Surface carboxyl probe groups can be derivative
- Ability to strip and re- probe
Binding Interaction Hydrophobic & Electrostatic Hydrophobic &
Electrostatic
Detection methods Radiolabeled Probes, Enzyme-antibody Radiolabeled Probes.
Conjugates - Chemiluminescent - Enzyme-antibody Chromogenic Conjugates
Chromogenic
The membrane A performs better since its net charge can be controlled by the pH activity of the chemical reaction. The change in net charge is adaptable in Membrane A which helps in the signal strength as the current flow can be high, as most of the time membrane A remains neutral whereas Membrane C has a negative charge with it that inhibits the current, which is also observed in the experimental results.
Sensitivity and lower concentration detection is possible in Membrane A. This is because Membrane A is a nylon based filter and does not contain any functional groups or charges, making the membrane A non-functionalised, providing a great response to analyte monitoring. While Membrane C also contains nylon material, it has charges and functional groups for derivatization.
The results are shown in Figure 19.
Noise Level with respect to Membranes
During the first 30 min of the experimental analysis, glucose was not dispensed. The signal obtained during this period is studied to see baseline noise signals in the system. The results are shown in Figure 20.
These baseline signals observed do not appear to have a pattern. Moreover, the Membrane A and Membrane C responses to these signals are not well defined. It is concluded that Membrane A and Membrane C have a baseline noise level, which is therefore an innate but variable characteristic, but importantly it is significantly less, almost an order of magnitude less than the noise levels observed with hydrogel based systems.
Substantiation of Data based on Human studies of Continuous Glucose Measurements using the Device of this Invention
The device was used with membranes A and C in a human study in an insulin-dependent diabetic subject. The glucose measurements were taken once every 5 minutes over a period of up to 10 hours, during continuous device application to the arm of the patient. Finger prick glucose measurements were also taken at pre-defined time intervals of up to hourly frequency. Two devices were worn simultaneously, one on each arm to measure precision as well as accuracy. The results are summarised in the table below, and also shown in figures 21 to 24.
Figure imgf000018_0001
100min Decreasing Only one watch had Acceptable
exponential a response
Parabolic One Watch had no None
shape/Unsure
whether Noise
Decreasing Very Good Very strong exponential correlation correlation
therefore precision
Observations
Results from these tests are shown in Figures 21 to 24, and the data shows that both accuracy and precision is enhanced, and initial noise level reduced where the device uses Membrane A compared with using Membrane C. The properties of membrane A are therefore a preferred embodiment of the invention.

Claims

1. An analyte-monitoring device comprising:
a porous membrane layer;
an analyte monitoring means; and
an enzyme deposited on the porous membrane layer and/or the analyte monitoring means;
wherein, when placed on the skin of a patient the membrane layer is an interface between the skin of the patient and the analyte monitoring means.
2. The device of Claim 1 wherein the porous membrane layer comprises or consists of nylon.
3. The device of Claim 1 or 2, wherein the analyte is glucose or lactate.
4. The device of any preceding claim, wherein the device does not comprise a gel.
5. The device of any preceding claim, wherein the device does not comprise a hydrogel. 6. The device of Claims 4 or 5, wherein the porous membrane layer does not include a gel and/or a hydrogel.
7. The device of any preceding claim, wherein the device is configured to continuously monitor the concentration of the analyte in a patient.
8. The device of any preceding claim, wherein the enzyme is glucose oxidase or lactase dehydrogenase.
9. The device of any preceding claim, wherein the enzyme has a concentration range in the porous membrane layer of 0.45 to 0.60 mg/cm2 of membrane surface area for a membrane thickness of 158 to 192 μηι thickness, or 0.45 mg to 0.60 mg per 0.158 μηι3 to 0.192μηι3 of the 3-dimensional porous membrane.
10. The device of any preceding claim wherein the analyte monitoring means includes an electrode, the enzyme being deposited on the electrode.
1 1. The device of any one of Claims 1 to 9, wherein the enzyme is deposited on the membrane layer by being either physically adsorbed on the porous membrane layer or chemically bonded to the porous membrane layer. 12. The device of Claim 1 , wherein the porous membrane layer is a porous hydrophilic polymer layer, optionally wherein the polymer is nylon, preferably nylon 6,6, and more preferably amphoteric nylon 6,6.
13. The device of Claim 1 , wherein the porous membrane layer is a porous hydrophobic, or partially hydrophobic layer, optionally wherein the polymer is chemically or physically treated nylon 6,6, or surface functionalised polyethersulfone.
14. The device of Claim 1 , wherein the porous membrane layer is a 3-dimensional matrix, optionally wherein the 3-dimensional matrix is nylon 6,6, or surface functionalised polyethersulfone.
15. The device of any preceding claim, wherein the porous membrane layer has a thickness of less than 300 μηι. 16. The device of any preceding claim, wherein the pores of the porous membrane layer have an average size of from about 0.1 μηι to about 2.0 μηι, such as from about 0.2 μηι to about 1.0 μηι, preferably from about 0.3 μηι to about 0.5 μηι.
17. The device of any preceding claim, wherein the porous membrane layer and analyte monitoring means are contiguous.
18. The device of any preceding claim, wherein when placed on the surface of the skin of a patient, the porous membrane layer and the surface of the skin are contiguous. 19. The device of any preceding claim, wherein the device comprises means for performing iontophoresis, ultrasound, and/or micro-poration using microneedles or laser light.
20. The device of any preceding claim, wherein the analyte monitoring means comprises a counter electrode and a working electrode, and a reference electrode. in a patient.
22. A method of monitoring the concentration of an analyte in a patient comprising the steps of:
a) applying a device according to any of Claims 1 to 20 to the skin of the patient such that the porous membrane layer of the device is hydrated and in contact with the skin; b) receiving analyte from the skin into the porous membrane layer;
c) converting the received analyte via the enzyme deposited in the porous membrane layer and/or on the analyte monitoring means; and
d) generating a signal representative of the level of received analyte via the analyte monitoring means.
23. The method of Claim 22, wherein the method involves the step of providing a porous membrane layer comprises or consists of nylon.
24. The method of Claim 22 or 23, wherein the method involves the step of performing iontophoresis or applying ultrasound to the skin, or poration of the skin by laser light or micro needles, in order to receive analyte.
25. The method of Claim 24 wherein the step of performing iontophoresis or applying ultrasound to the skin, or poration of the skin by laser light or micro needles is performed prior to application of the device to the skin. 26. The method of any one of Claims 22 to 25, wherein the analyte is glucose or lactate, comprising the step of oxidising the received glucose or lactate to produce hydrogen peroxide.
27. The method of Claim 26, comprising the step of detecting the level of hydrogen peroxide produced by the analyte monitoring means.
PCT/GB2018/050384 2017-02-14 2018-02-13 Analyte-monitoring device WO2018150168A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1702405.0A GB2559627A (en) 2017-02-14 2017-02-14 Device
GB1702405.0 2017-02-14

Publications (1)

Publication Number Publication Date
WO2018150168A1 true WO2018150168A1 (en) 2018-08-23

Family

ID=58462039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2018/050384 WO2018150168A1 (en) 2017-02-14 2018-02-13 Analyte-monitoring device

Country Status (2)

Country Link
GB (1) GB2559627A (en)
WO (1) WO2018150168A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048834A1 (en) * 2003-11-13 2005-06-02 Medtronic Minimed, Inc. Long term analyte sensor array
WO2008109739A1 (en) * 2007-03-07 2008-09-12 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
WO2009053911A2 (en) * 2007-10-23 2009-04-30 Sensile Pat Ag Medical device for glucose monitoring or regulation
WO2013144255A1 (en) * 2012-03-27 2013-10-03 F. Hoffmann-La Roche Ag Improved spacer membrane for an enzymatic in-vivo sensor
WO2014210481A1 (en) * 2013-06-28 2014-12-31 Google Inc. Porous polymeric formulation prepared using porogens
WO2016187320A1 (en) * 2015-05-18 2016-11-24 Milo Sensors, Inc. Transdermal analyte sensing device

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503198B1 (en) * 1997-09-11 2003-01-07 Jack L. Aronowtiz Noninvasive transdermal systems for detecting an analyte obtained from or underneath skin and methods
AU2002300167B2 (en) * 1997-09-11 2006-08-31 Jack L. Aronowitz Noninvasive Transdermal Systems for Detecting Analytes
AU6035299A (en) * 1998-09-09 2000-03-27 Amira Medical Interstitial fluid methods and devices for determination of an analyte in the body
US7577469B1 (en) * 1999-03-11 2009-08-18 Jack L. Aronowitz Noninvasive transdermal systems for detecting an analyte in a biological fluid and methods
KR20070043768A (en) * 2004-07-01 2007-04-25 비보메디칼 인코포레이티드 Non-invasive glucose measurement

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048834A1 (en) * 2003-11-13 2005-06-02 Medtronic Minimed, Inc. Long term analyte sensor array
WO2008109739A1 (en) * 2007-03-07 2008-09-12 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
WO2009053911A2 (en) * 2007-10-23 2009-04-30 Sensile Pat Ag Medical device for glucose monitoring or regulation
WO2013144255A1 (en) * 2012-03-27 2013-10-03 F. Hoffmann-La Roche Ag Improved spacer membrane for an enzymatic in-vivo sensor
WO2014210481A1 (en) * 2013-06-28 2014-12-31 Google Inc. Porous polymeric formulation prepared using porogens
WO2016187320A1 (en) * 2015-05-18 2016-11-24 Milo Sensors, Inc. Transdermal analyte sensing device

Also Published As

Publication number Publication date
GB2559627A (en) 2018-08-15
GB201702405D0 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
Wang et al. A thin film polyethylene terephthalate (PET) electrochemical sensor for detection of glucose in sweat
Chinnadayyala et al. Nonenzymatic determination of glucose at near neutral pH values based on the use of nafion and platinum black coated microneedle electrode array
JP5815652B2 (en) Sensor assembly for analyte monitoring system using hydrogel and analyte monitoring method using sensor assembly
Ali et al. A fast and sensitive potentiometric glucose microsensor based on glucose oxidase coated ZnO nanowires grown on a thin silver wire
US9968284B2 (en) Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device
JP5502279B2 (en) System and method for analyte sampling and analysis using hydrogels
CN111989042A (en) Lactate sensor and related methods
US20150122646A1 (en) Mediator-less Electrochemical Glucose Sensing Procedure Employing the Leach-proof Covalent Binding of an Enzyme(s) to Electrodes and Products Thereof
CN102112873B (en) Composition for glucose sensing comprising of nanofibrous membrane and method for manufacturing non-enzymatic glucose biosensor using same
JP7480234B2 (en) Analyte sensor and method for detecting creatinine - Patent Application 20070123333
WO2011084607A1 (en) Transdermal systems, devices, and methods for biological analysis
Wang et al. Towards a transdermal membrane biosensor for the detection of lactate in body fluids
Zheng et al. Rapid and simple preparation of a reagentless glucose electrochemical biosensor
Ambrózy et al. Protective membranes at electrochemical biosensors
KR102290253B1 (en) Bio sensor and manufacturing method thereof
Naskar et al. Electrochemical detection of eugenol (EU) using polyacrylonitrile molecular imprinted polymer embedded graphite (PAN-MIP/G) electrode
Cetinkaya et al. A collection of the best practice examples of electroanalytical applications in education: from polarography to sensors
WO2019176339A1 (en) Protective film material for biosensor probe
Li et al. Potential of a simple lab-on-a-tube for point-of-care measurements of multiple analytes
WO2018150168A1 (en) Analyte-monitoring device
Liu et al. Os-complex-based amperometric bienzyme biosensor for continuous determination of lactate in saliva
Ozoemena et al. Metallophthalocyanine Based Carbon Paste Electrodes for the Determination of 2′, 3′‐Dideoxyinosine
KR20140143999A (en) Disposable amperometric detection of glycated hemoglobin
Zhang et al. Flexible cellulose paper-based biosensor from inkjet printing for non-invasive glucose monitoring
CN109959688B (en) Method for simultaneously detecting dopamine and uric acid based on poly-L-glutathione modified glassy carbon electrode

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18706551

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WA Withdrawal of international application